Cargando…
Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas
BACKGROUND: Matrix metalloproteinases (MMPs) are enzymes that promote tumor invasion and angiogenesis by enzymatically remodeling the extracellular matrix. MMP-2 and MMP-9 are the most abundant forms of MMPs in malignant gliomas, while a 130 kDa MMP is thought to be MMP-9 complexed to other proteina...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2263020/ https://www.ncbi.nlm.nih.gov/pubmed/18186943 http://dx.doi.org/10.1186/1743-8454-5-1 |
_version_ | 1782151429331353600 |
---|---|
author | Wong, Eric T Alsop, David Lee, Diana Tam, Angela Barron, Loretta Bloom, Julianne Gautam, Shiva Wu, Julian K |
author_facet | Wong, Eric T Alsop, David Lee, Diana Tam, Angela Barron, Loretta Bloom, Julianne Gautam, Shiva Wu, Julian K |
author_sort | Wong, Eric T |
collection | PubMed |
description | BACKGROUND: Matrix metalloproteinases (MMPs) are enzymes that promote tumor invasion and angiogenesis by enzymatically remodeling the extracellular matrix. MMP-2 and MMP-9 are the most abundant forms of MMPs in malignant gliomas, while a 130 kDa MMP is thought to be MMP-9 complexed to other proteinases. This study determined whether doxycycline can block MMP activity in vitro. We also measured MMP-2 and MMP-9 levels in cerebrospinal fluid (CSF) from patients with recurrent malignant gliomas. METHODS: To determine whether doxycycline can block MMP activity, we measured the extent of doxycyline-mediated MMP-2 and MMP-9 inhibition in vitro using epidermal growth factor receptor (EGFR) transfected U251 glioma cell lines. MMP activity was measured using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography. In addition, patients underwent lumbar puncture for CSF sampling at baseline, after 6 weeks (1 cycle), and after 12 weeks (2 cycles), while being treated with a novel chemotherapy regimen of irinotecan, thalidomide, and doxycycline designed to block growth/proliferation, angiogenesis, and invasion. Irinotecan was given at 125 mg/m(2)/week for 4 weeks in 6-week cycles, together with continuous doxycycline at 100 mg twice daily on Day 1 and 50 mg twice daily thereafter. Daily thalidomide dose in our cohort was 400 mg. Tumor progression was monitored by magnetic resonance imaging (MRI). RESULTS: Doxycyline in vitro completely abolished MMP-9 activity at 500 μg/ml while there was only 30 to 50% inhibition of MMP-2 activity. Four patients respectively completed 4, 3, 1, and 2 cycles of irinotecan, thalidomide, and doxycycline. Patient enrollment was terminated after one patient developed radiologically defined pulmonary embolism, and another had probable pulmonary embolism. Although CSF MMP-2 and 130 kDa MMP levels were stable, MMP-9 level progressively increased during treatment despite stable MRI. CONCLUSION: Doxycycline can block MMP-2 and MMP-9 activities from glioma cells in vitro. Increased CSF MMP-9 activity could be a biomarker of disease activity in patients with malignant gliomas, before any changes are detectable on MRI. |
format | Text |
id | pubmed-2263020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-22630202008-03-06 Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas Wong, Eric T Alsop, David Lee, Diana Tam, Angela Barron, Loretta Bloom, Julianne Gautam, Shiva Wu, Julian K Cerebrospinal Fluid Res Research BACKGROUND: Matrix metalloproteinases (MMPs) are enzymes that promote tumor invasion and angiogenesis by enzymatically remodeling the extracellular matrix. MMP-2 and MMP-9 are the most abundant forms of MMPs in malignant gliomas, while a 130 kDa MMP is thought to be MMP-9 complexed to other proteinases. This study determined whether doxycycline can block MMP activity in vitro. We also measured MMP-2 and MMP-9 levels in cerebrospinal fluid (CSF) from patients with recurrent malignant gliomas. METHODS: To determine whether doxycycline can block MMP activity, we measured the extent of doxycyline-mediated MMP-2 and MMP-9 inhibition in vitro using epidermal growth factor receptor (EGFR) transfected U251 glioma cell lines. MMP activity was measured using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) zymography. In addition, patients underwent lumbar puncture for CSF sampling at baseline, after 6 weeks (1 cycle), and after 12 weeks (2 cycles), while being treated with a novel chemotherapy regimen of irinotecan, thalidomide, and doxycycline designed to block growth/proliferation, angiogenesis, and invasion. Irinotecan was given at 125 mg/m(2)/week for 4 weeks in 6-week cycles, together with continuous doxycycline at 100 mg twice daily on Day 1 and 50 mg twice daily thereafter. Daily thalidomide dose in our cohort was 400 mg. Tumor progression was monitored by magnetic resonance imaging (MRI). RESULTS: Doxycyline in vitro completely abolished MMP-9 activity at 500 μg/ml while there was only 30 to 50% inhibition of MMP-2 activity. Four patients respectively completed 4, 3, 1, and 2 cycles of irinotecan, thalidomide, and doxycycline. Patient enrollment was terminated after one patient developed radiologically defined pulmonary embolism, and another had probable pulmonary embolism. Although CSF MMP-2 and 130 kDa MMP levels were stable, MMP-9 level progressively increased during treatment despite stable MRI. CONCLUSION: Doxycycline can block MMP-2 and MMP-9 activities from glioma cells in vitro. Increased CSF MMP-9 activity could be a biomarker of disease activity in patients with malignant gliomas, before any changes are detectable on MRI. BioMed Central 2008-01-11 /pmc/articles/PMC2263020/ /pubmed/18186943 http://dx.doi.org/10.1186/1743-8454-5-1 Text en Copyright © 2008 Wong et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Wong, Eric T Alsop, David Lee, Diana Tam, Angela Barron, Loretta Bloom, Julianne Gautam, Shiva Wu, Julian K Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas |
title | Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas |
title_full | Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas |
title_fullStr | Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas |
title_full_unstemmed | Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas |
title_short | Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas |
title_sort | cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2263020/ https://www.ncbi.nlm.nih.gov/pubmed/18186943 http://dx.doi.org/10.1186/1743-8454-5-1 |
work_keys_str_mv | AT wongerict cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas AT alsopdavid cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas AT leediana cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas AT tamangela cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas AT barronloretta cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas AT bloomjulianne cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas AT gautamshiva cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas AT wujuliank cerebrospinalfluidmatrixmetalloproteinase9increasesduringtreatmentofrecurrentmalignantgliomas |